Clinical utility of reticulocyte hemoglobin equivalent in patients with heart failure

Figures

• 

  Figure 1. Prevalence rate of anemia, iron deficiency, and iron deficiency anemia in HF patients. Prevalence rate of (A) anemia, (B) ID, and (C) IDA in all HF patients. ID iron deficiency, IDA iron deficiency anemia.

• 

  Figure 2. Correlation between Ret-He levels and serum iron, TSAT, serum ferritin, and Hb levels in HF patients. Correlation between Ret-He levels and (A) serum iron, (B) TSAT, (C), Hb, (D) ferritin, and (E) an expanded Y-axis in ferritin 0-500 μg/L in HF patients. TSAT transferrin saturation, Hb hemoglobin.

• 

  Figure 3. Ret-He levels in HF patients with and without iron deficiency. (A) Ret-He levels in HF patients with (n = 92) and without ID (n = 50). (B) ROC curve of Ret-He to screen for ID. (C) Ret-He levels in HF patients with (n = 82) and without (n = 60) IDA. (D) ROC curve of Ret-He to screen for IDA. ID iron deficiency, IDA iron deficiency anemia, AUC area under the curve, TPF true positive fraction, FPF false positive fraction.

• 

  Figure 4. Survival curves for all-cause death or heart failure readmission according to quartile of Ret-He levels in HF patients. Kaplan–Meier analysis for (A) all-cause death or HF readmission, (B) all-cause death, and (C) HF readmission in HF patients by quartile of Ret-He levels.

• 

  Figure 5. Survival curves for all-cause death or heart failure readmission according to a three-group classification of change in Ret-He levels between admission and discharge in HF patients. Kaplan–Meier analysis for (A) all-cause death or HF readmission, (B) all-cause death, and (C) HF readmission in HF patients by a three-group classification of change in Ret-He levels between admission and discharge (ΔRet-He).